KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 91 filers reported holding KARYOPHARM THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.88 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $102,000 | 0.0% | 18,857 | +7.1% | 0.00% | 0.0% |
Q3 2021 | $102,000 | -94.6% | 17,613 | -90.1% | 0.00% | -95.7% |
Q1 2021 | $1,880,000 | +132.1% | 178,704 | +318.7% | 0.02% | +109.1% |
Q2 2020 | $810,000 | +180.3% | 42,680 | +183.9% | 0.01% | -38.9% |
Q1 2020 | $289,000 | -82.7% | 15,036 | -82.7% | 0.02% | -56.1% |
Q4 2019 | $1,669,000 | -39.1% | 87,067 | -69.5% | 0.04% | -48.8% |
Q3 2019 | $2,742,000 | +348.0% | 285,100 | +172.0% | 0.08% | +281.0% |
Q1 2019 | $612,000 | -46.8% | 104,800 | -14.7% | 0.02% | -52.3% |
Q4 2018 | $1,151,000 | -83.8% | 122,800 | -70.6% | 0.04% | -86.1% |
Q3 2018 | $7,121,000 | +0.8% | 418,100 | +0.6% | 0.32% | -17.2% |
Q2 2018 | $7,061,000 | +44.1% | 415,600 | +0.7% | 0.38% | +4.4% |
Q1 2018 | $4,900,000 | +104.2% | 412,892 | +65.2% | 0.37% | +86.3% |
Q4 2017 | $2,400,000 | -12.6% | 250,000 | 0.0% | 0.20% | -21.5% |
Q3 2017 | $2,745,000 | -6.7% | 250,000 | -23.1% | 0.25% | -17.2% |
Q2 2017 | $2,941,000 | -32.6% | 325,000 | -4.4% | 0.30% | -30.8% |
Q1 2017 | $4,366,000 | – | 340,000 | – | 0.44% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Palo Alto Investors LP | 3,200,396 | $30,084,000 | 1.72% |
TFS CAPITAL LLC | 105,040 | $987,000 | 0.26% |
Tekla Capital Management LLC | 500,324 | $4,703,000 | 0.20% |
Piermont Capital Management Inc. | 51,080 | $480,000 | 0.11% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 55,793 | $524,000 | 0.09% |
Candriam S.C.A. | 390,000 | $3,666,000 | 0.08% |
Virtus ETF Advisers LLC | 27,446 | $258,000 | 0.08% |
SECOR Capital Advisors, LP | 66,484 | $625,000 | 0.08% |
Trexquant Investment LP | 29,007 | $273,000 | 0.04% |
PRELUDE CAPITAL MANAGEMENT, LLC | 32,196 | $303,000 | 0.04% |